Cargando…

Pooled solifenacin overactive bladder trial data: Creation, validation and analysis of an integrated database

BACKGROUND: Patient-level data are available for 11 randomized, controlled, Phase III/Phase IV solifenacin clinical trials. METHODS: Meta-analyses were conducted to interrogate the data, to broaden knowledge about solifenacin and overactive bladder (OAB) in general. Before integrating data, datasets...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chapple, Christopher R., Cardozo, Linda, Snijder, Robert, Siddiqui, Emad, Herschorn, Sender
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2016
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5935888/ https://www.ncbi.nlm.nih.gov/pubmed/29736483 http://dx.doi.org/10.1016/j.conctc.2016.10.003

Ejemplares similares

Cardiovascular safety in refractory incontinent patients with overactive bladder receiving add‐on mirabegron therapy to solifenacin (BESIDE)
por: Drake, Marcus J., et al.
Publicado: (2017)

Solifenacin significantly improves all symptoms of overactive bladder syndrome
por: CHAPPLE, C R, et al.
Publicado: (2006)

Long‐term treatment of older patients with overactive bladder using a combination of mirabegron and solifenacin: a prespecified analysis from the randomized, phase III SYNERGY II study
por: Mueller, Elizabeth R., et al.
Publicado: (2019)

Comparison of solifenacin and fesoterodine in treatment of overactive bladder
por: Ercan, Önder, et al.
Publicado: (2015)

Onset of action of the β3-adrenoceptor agonist, mirabegron, in Phase II and III clinical trials in patients with overactive bladder
por: Chapple, Christopher R., et al.
Publicado: (2014)

Pharmacokinetics of solifenacin in pediatric populations with overactive bladder or neurogenic detrusor overactivity
por: Tannenbaum, Stacey, et al.
Publicado: (2020)

What are the chances of improvement or cure from overactive bladder? A pooled responder analysis of efficacy and treatment emergent adverse events following treatment with fesoterodine
por: Wagg, Adrian S., et al.
Publicado: (2021)

Solifenacin in Multiple Sclerosis Patients with Overactive Bladder: A Prospective Study
por: van Rey, Farida, et al.
Publicado: (2011)

Tamsulosin and Solifenacin in the Treatment of Benign Prostatic Hyperplasia in combination with overactive bladder
por: Wang, Hui, et al.
Publicado: (2017)

A Comparative Study of Solifenacin, Mirabegron, and Their Combination as Bladder Relaxants in the Management of Overactive Bladder
por: Kumar, Shailendra, et al.
Publicado: (2023)

Meta-Analysis of the Efficacy and Safety of Mirabegron Add-On Therapy to Solifenacin for Overactive Bladder
por: Xu, Yankai, et al.
Publicado: (2017)

Solifenacin versus posterior tibial nerve stimulation for overactive bladder in patients with multiple sclerosis
por: Majdinasab, Nastaran, et al.
Publicado: (2023)

Relationship between mean volume voided and incontinence in children with overactive bladder treated with solifenacin: post hoc analysis of a phase 3 randomised clinical trial
por: Snijder, Robert, et al.
Publicado: (2020)

Clinical Factors Associated With Dose Escalation of Solifenacin for the Treatment of Overactive Bladder in Real Life Practice
por: Chun, Ji-Youn, et al.
Publicado: (2014)

Cost-effectiveness of solifenacin compared with oral antimuscarinic agents for the treatment of patients with overactive bladder in the UK
por: Hakimi, Zalmai, et al.
Publicado: (2018)

Influence of Daytime or Nighttime Dosing with Solifenacin for Overactive Bladder with Nocturia: Impact on Nocturia and Sleep Quality
por: Kwon, Taekmin, et al.
Publicado: (2017)

Efficacy and tolerability of mirabegron compared with solifenacin for children with idiopathic overactive bladder: A preliminary study
por: Kim, Seong Cheol, et al.
Publicado: (2021)

OnabotulinumtoxinA 100U provides significant improvements in overactive bladder symptoms in patients with urinary incontinence regardless of the number of anticholinergic therapies used or reason for inadequate management of overactive bladder
por: Sievert, K-D, et al.
Publicado: (2014)

Transcutaneous electrical nerve stimulation and solifenacin succinate versus solifenacin succinate alone for treatment of overactive bladder syndrome: A double-blind randomized controlled study
por: Zhang, Yumeng, et al.
Publicado: (2021)

Mirabegron for the treatment of overactive bladder: a prespecified pooled efficacy analysis and pooled safety analysis of three randomised, double-blind, placebo-controlled, phase III studies
por: Nitti, V W, et al.
Publicado: (2013)

Efficacy and safety of solifenacin succinate in Korean patients with overactive bladder: a randomised, prospective, double-blind, multicentre study
por: Choo, M-S, et al.
Publicado: (2008)

Efficacy and safety of combination of mirabegron and solifenacin in patients with double-J stent related overactive bladder: a prospective study
por: Tang, Qing-lai, et al.
Publicado: (2022)

Mirabegron in the Management of Overactive Bladder Syndrome
por: O’Kane, Miriam, et al.
Publicado: (2022)

Safety and Tolerability Results from the PILLAR Study: A Phase IV, Double-Blind, Randomized, Placebo-Controlled Study of Mirabegron in Patients ≥ 65 years with Overactive Bladder-Wet
por: Herschorn, Sender, et al.
Publicado: (2020)

Recent advances in managing overactive bladder
por: Araklitis, George, et al.
Publicado: (2020)

Health economics perspective of fesoterodine, tolterodine or solifenacin as first-time therapy for overactive bladder syndrome in the primary care setting in Spain
por: Sicras-Mainar, Antoni, et al.
Publicado: (2013)

Clinical Efficacy of Solifenacin in the Management of Diabetes Mellitus-Associated Versus Idiopathic Overactive Bladder Symptoms: A Multicenter Prospective Study
por: Choi, Hoon, et al.
Publicado: (2018)

Real life persistence rate with antimuscarinic treatment in patients with idiopathic or neurogenic overactive bladder: a prospective cohort study with solifenacin
por: Tijnagel, Marloes J., et al.
Publicado: (2017)

Effect of electroacupuncture versus solifenacin for moderate and severe overactive bladder: a multi-centre, randomized controlled trial study protocol
por: Wen, Qian, et al.
Publicado: (2020)

Impact of mirabegron versus solifenacin on autonomic function and arterial stiffness in female overactive bladder syndrome: a randomized controlled trial
por: Hsiao, Sheng-Mou, et al.
Publicado: (2022)

Cognitive Effects of Anticholinergic Load in Women with Overactive Bladder
por: Araklitis, George, et al.
Publicado: (2020)

Validation of a bladder symptom screening tool in women with incontinence due to overactive bladder
por: Cardozo, Linda, et al.
Publicado: (2014)

A prospective, double-blind, randomized, two-period crossover, multicenter study to evaluate tolerability and patient preference between mirabegron and tolterodine in patients with overactive bladder (PREFER study)
por: Staskin, David, et al.
Publicado: (2017)

Patient-reported outcomes in patients with overactive bladder treated with mirabegron and tolterodine in a prospective, double-blind, randomized, two-period crossover, multicenter study (PREFER)
por: Herschorn, Sender, et al.
Publicado: (2018)

Overactive bladder syndrome: Current pathophysiological concepts and therapeutic approaches
por: Osman, Nadir I., et al.
Publicado: (2013)

Efficacy and safety of fesoterodine 8 mg in subjects with overactive bladder after a suboptimal response to tolterodine ER
por: Kaplan, S A, et al.
Publicado: (2014)

Effect of mirabegron on cognitive function in elderly patients with overactive bladder: MoCA results from a phase 4 randomized, placebo-controlled study (PILLAR)
por: Griebling, Tomas L., et al.
Publicado: (2020)

Non-invasive transcutaneous electrical stimulation in the treatment of overactive bladder
por: Slovak, Martin, et al.
Publicado: (2015)

Effectiveness of Solifenacin for Managing of Bladder Spasms in Patients With Urethroplasty
por: Peng, Xu Feng, et al.
Publicado: (2017)

The Add-On Effect of Solifenacin for Patients with Remaining Overactive Bladder after Treatment with Tamsulosin for Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Obstruction
por: Masumori, Naoya, et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_dp57ts7dha6uk8jnfsctop1hno